News

NEW YORK, NY, September 11, 2025 - Royalty Pharma plc will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to drive shareholder value creation through its unique business model and capabilities in the large and growing market for funding biopharma innovation with royalties.

NEW YORK, NY, September 10, 2025 – Royalty Pharma plc today announced the release of a biopharma royalty market study conducted by Deloitte.

NEW YORK, NY, September 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.

NEW YORK, NY, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)...

NEW YORK, NY, and WALTHAM, MA, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.

NEW YORK, NY, August 25, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront.

NEW YORK, NY, August 13, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.

NEW YORK, NY, August 6, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

NEW YORK, NY, July 18, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.

NEW YORK, NY, July 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately.